Cancer Biology

793 Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers.

792 A pathology atlas of the human cancer transcriptome.

791 An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

790 FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.

789 A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients.

788 In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

787 Genome editing abrogates angiogenesis in vivo.

786 A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

785 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

784 An immunogenic personal neoantigen vaccine for patients with melanoma.

783 Contrary to expectation, lymphatic and distant metastases often arise independently in human colorectal cancer.

782 Identification of the cell types from which relapse arises in acute myeloid leukaemia, by following leukaemia propagation from patient-derived leukaemia samples.

781 Applying a new, more sensitive single-cell transcriptomics method to diagnosis, remission and progression samples from patients with chronic myeloid leukemia reveals insight into the heterogeneity of cells that resist treatment with targeted therapy, as well as into the dynamics of disease progression and its effects on nontransformed hematopoietic stem cells.

780 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

779 Genetically engineered ‘lymphoreporter’ mouse strains are used to track melanoma dissemination in vivo, identifying midkine as a tumour-secreted factor that acts at a distance, preparing pre-metastatic niches and serving as an indicator of poor prognosis in patients.

778 Metastatic progression of colorectal cancer is modeled in mice using in vivo genome editing and transplantation of engineered organoids.

777 Genetically engineered colon organoids form tumors that undergo a stepwise progression toward metastatic disease after orthotopic transplantation.

776 Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.

775 Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

774 argeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.

Free Images for Presentation: sunipix SUNIPIX